Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed · Phase 1/Phase 2

Conditions studied: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma

In brief

This phase I/II trial studies the side effects and best dose of vorinostat when given together with temozolomide and radiation therapy and to see how well they work in treating patients with newly diagnosed glioblastoma multiforme. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving vorinostat together with temozolomide and radiation therapy may kill more tumor cells.

Key facts

Study ID

NCT00731731

Run by

National Cancer Institute (NCI)

People needed

125

Starts

2009-07-10

Expected to finish

2019-11-01

Last updated by the study team

2022-08-04

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PRE-REGISTRATION:
• Central pathology review submission; this review is mandatory prior to registration to confirm eligibility; it should be initiated as soon after surgery as possible
• Treatment should begin >= 2 weeks and =< 5 weeks following surgery
• REGISTRATION:
• Histologically confirmed glioblastoma multiforme as determined by pre-registration central pathology review; Note: gliosarcomas and other grade 4 astrocytoma variants (e.g., giant cell) are eligible
• Measurable or evaluable disease by gadolinium magnetic resonance imaging (MRI) or contrast computed tomography (CT) scan; Note: patients who have had a gross total resection (GTR) are eligible on the basis of evaluable disease
• Must begin partial brain radiotherapy on the same day that vorinostat and temozolomide begin
• Karnofsky performance status of >= 60
• Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
• Absolute neutrophil count (ANC) >= 1,500/mm\^3
• Platelet count >= 100,000/mm\^3
• White blood cell (WBC) >= 3,000/mm\^3
• Hemoglobin >= 10.0 g/dL; Note: this level may be reached by transfusion
• Total bilirubin =< 2.0 x institutional upper limit of normal (ULN)
• Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.0 x ULN
• Creatinine =< 1.5 mg/dL
• Life expectancy >= 12 weeks
• Negative serum pregnancy test done =< 7 days prior to registration, for women of childbearing potential only
• For Phase I established MTD and Phase II patients only: Willing and able to complete neurocognitive testing
• Ability to provide informed written consent
• Willing to return to Alliance or Adult Brain Tumor Consortium (ABTC) enrolling institution for follow-up
• Phase I established MTD patients and Phase II patients: Willing to provide mandatory tissue samples (slides or blocks) for research purposes
• Willing to forego other cytotoxic and non-cytotoxic drug therapy against the tumor while being treated with vorinostat and temozolomide

You may not qualify if…

• Any of the following:
• Pregnant women
• Nursing women
• Men or women of childbearing potential who are unwilling to employ adequate contraception throughout the duration of the study and for 12 weeks after treatment has ended
• Prior cytotoxic drug therapy, non-cytotoxic drug therapy, or experimental drug therapy for brain tumors
• Prior cranial RT
• Prior Gliadel wafers
• Known hypersensitivity to any of the components of vorinostat or other agents used in study
• Valproic acid, another histone deacetylase inhibitor, =< 2 weeks prior to registration and during treatment
• Other active malignancy =< 3 years prior to registration; Exception: non-melanotic skin cancer or carcinoma in situ of the cervix; Note: if there is a history of prior malignancy, they must not be receiving other specific treatment (other than hormonal therapy) for their cancer
• Uncontrolled infection
• Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy; Note: patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial
• Co-morbid systemic illness or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with proper assessment of safety and adverse events of the prescribed regimens
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit compliance with study requirements
• History of myocardial infarction or unstable angina =< 6 months prior to registration or congestive heart failure (CHF) requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
• New York Heart Association (NYHA) >= Class II Congestive Heart Failure
• Inability to take oral medications
• Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
• Congenital long QT syndrome
• Prolonged corrected (QTc) interval (> 450 msec)
• Any of the following Category I drugs that are generally accepted to have a risk of causing Torsades de Pointes =< 7 days prior to registration
• Quinidine, procainamide, disopyramide
• Amiodarone, sotalol, ibutilide, dofetilide
• Erythromycin, clarithromycin
• Chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide

Where it is running

• UCSF Medical Center-Parnassus — San Francisco, California, United States
• Mayo Clinic in Florida — Jacksonville, Florida, United States
• AdventHealth Orlando — Orlando, Florida, United States
• Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia, United States
• Hawaii Cancer Care Inc - Waterfront Plaza — Honolulu, Hawaii, United States
• Queen's Medical Center — Honolulu, Hawaii, United States
• Straub Clinic and Hospital — Honolulu, Hawaii, United States
• University of Hawaii Cancer Center — Honolulu, Hawaii, United States
• Kuakini Medical Center — Honolulu, Hawaii, United States
• Queen's Cancer Center - Kuakini — Honolulu, Hawaii, United States
• The Cancer Center of Hawaii-Liliha — Honolulu, Hawaii, United States
• Kapiolani Medical Center for Women and Children — Honolulu, Hawaii, United States
• Castle Medical Center — Kailua, Hawaii, United States
• Wilcox Memorial Hospital and Kauai Medical Clinic — Lihue, Hawaii, United States
• Pali Momi Medical Center — ‘Aiea, Hawaii, United States
• Queen's Cancer Center - Pearlridge — ‘Aiea, Hawaii, United States
• Rush University Medical Center — Chicago, Illinois, United States
• Presence Resurrection Medical Center — Chicago, Illinois, United States
• Garneau, Stewart C MD (UIA Investigator) — Moline, Illinois, United States
• Porubcin, Michael MD (UIA Investigator) — Moline, Illinois, United States
• Sharis, Christine M MD (UIA Investigator) — Moline, Illinois, United States
• Spector, David MD (UIA Investigator) — Moline, Illinois, United States
• Stoffel, Thomas J MD (UIA Investigator) — Moline, Illinois, United States
• Trinity Medical Center — Moline, Illinois, United States
• Mayo Clinic in Arizona — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.